Our findings suggest that the activity of the p53-mediated DNA damage response pathway might be considered as a predictor of ICB therapy response as well, not only for lung cancer (LUAD and LUSC have the strongest associations), but also for other cancer types (Figure 3A). This evidence concerns the gene TP53 and lung cancer.